Neurological Surgery Doctors in Harrisburg, PA Accepting Medicare

8 Neurological Surgery doctors found. Showing 1 - 8

Bart Thaci, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 205 South Front Street, 6th Floor Bma, Harrisburg, PA 17104 Phone: 717-988-9370    Fax: 717-703-0154

Dr. Eva Flormarie Pamias Portalatin, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 205 S Front St, Harrisburg, PA 17104 Phone: 717-988-9370

Dr. Richard Kenneth Osenbach, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 4310 Londderry Road, Suite 202, Harrisburg, PA 17109 Phone: 717-791-2520    Fax: 717-920-4361

Dr. Chikezie Ikechukwu Eseonu, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 205 South Front Street, 6th Floor Bma, Harrisburg, PA 17104 Phone: 717-988-9370    Fax: 717-703-0154

Dr. Robert J Schlegel, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 205 S Front St Fl 6, Harrisburg, PA 17104 Phone: 717-988-9370    Fax: 717-703-0154

Rifaat M. Bashir, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 2645 N 3rd St, Harrisburg, PA 17110 Phone: 717-782-6421    Fax: 717-782-6410

Dr. William J Beutler, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 820 Sir Thomas Ct, Harrisburg, PA 17109 Phone: 717-652-9555    Fax: 717-657-9023

Dr. Corey Michael Gill, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 205 S. Front Street, Brady 3 Suite 3a, Harrisburg, PA 17104 Phone: 717-231-8722

News Archive

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2010. Total revenues for the second quarter of 2010 were $1.93 billion, up 17 percent compared to total revenues of $1.65 billion for the second quarter of 2009. Net income for the second quarter of 2010 was $712.1 million, or $0.79 per diluted share, compared to net income for the second quarter of 2009 of $571.4 million, or $0.61 per diluted share.

Scientists find 2 key proteins that regulate growth of mammary stem cells and contribute to breast cancer

By carefully controlling the levels of two proteins, researchers at the Salk Institute have discovered how to keep mammary stem cells-those that can form breast tissue-alive and functioning in the lab. The new ability to propagate mammary stem cells is allowing them to study both breast development and the formation of breast cancers.

Discovery of mechanism linking color vision and cancer genes

Biologists at New York University have discovered a system by which a random choice between two distinct cellular fates in the fruit fly eye becomes firmly established.

Nuevolution enters lead discovery collaboration for epigenetic disorders

Nuevolution A/S today announced that it has entered into a lead discovery collaboration focused on epigenetic disorders.A consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and the research group of Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) has been established with the objective of identifying and developing novel small molecule drugs against epigenetic factors.

Read more Medical News

› Verified 9 days ago